Health
Pfizer and BioNTech are submitting emergency use authorization request for their Covid-19 vaccine to the US FDA
Pfizer and BioNTech are submitting emergency use authorization request for their Covid-19 vaccine to the US FDA
Credit: Norbert Nagel, Mörfelden-Walldorf, Germany, via Wikimedia Commons (Creative Commons Attribution ShareAlike 3.0)

On Friday, Pfizer and BioNTech are submitting an emergency use authorization request for their Covid-19 vaccine to the US Food and Drug Administration. While it's unclear how long the process will take, the US government is expected to approve the vaccine until mid-December.

"The submission is based on a vaccine efficacy rate of 95% (p<0.0001) demonstrated in the companies’ Phase 3 clinical study in participants without prior SARS-CoV-2 infection (first primary objective) and also in participants with and without prior SARS-CoV-2 infection (second primary objective), in each case measured from 7 days after the second dose," Pfizer said in a statement posted on its website.

Health
Germany does not expect a Covid-19 vaccine to be available before first quarter 2021
Jens Spahn
Jens Spahn Credit: Heinrich-Böll-Stiftung (Creative Commons Attribution 2.0)

Germany's health minister Jens Spahn said he still does not expect a shot to be available before the first quarter of 2021, even after the announcement by Pfizer and its German partner BioNTech that their Covid-19 vaccine proved to be 90% effective.

"If this should prove true ... then it would be a good signal because it shows that this vaccine makes a difference," Jens Spahn told a news conference Monday.

Health
Covid-19: Pfizer and BioNTech vaccine offers 90% protection
Covid-19: Pfizer and BioNTech vaccine offers 90% protection
Credit: Illustration: Pendect, Logos Pfizer and BioNTech (Creative Commons Attribution ShareAlike 4.0)

According to a preliminary analysis, the vaccine developed by Pfizer and BioNTech can prevent more than 90% of people from getting Covid-19. However, the data presented is not the final analysis as it is based on only the first 94 volunteers to develop Covid-19 so the precise effectiveness of the vaccine may change when the full results are analysed.

The companies stated they would be able to supply 50 million doses by the end of this year and around 1.3 billion by the end of 2021. Each person needs two doses.

Dr Albert Bourla, the chairman of Pfizer, said: "We are a significant step closer to providing people around the world with a much-needed breakthrough to help bring an end to this global health crisis."